{"commentary":{"count":64,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":24,"youtube":20,"podcast":20},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04619004\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04619004","nct_id":"NCT04619004","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04619004. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV every 3 weeks (Q3W)","label":"Study Group 1: Patritumab deruxtecan 5.6 mg/kg","type":"EXPERIMENTAL"},{"description":"Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV every 3 weeks (Q3W)","label":"Study Group 2: Patritumab deruxtecan Up-Titration","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Co., Ltd.","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-01-04","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer Metastatic","Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor"],"enrollment":{"count":277,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Patritumab Deruxtecan (Fixed dose)","type":"DRUG"},{"name":"Patritumab Deruxtecan (Up-Titration)","type":"DRUG"}],"last_update":"2026-09-01","lead_sponsor":"Daiichi Sankyo","official_title":"HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-11-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months"}],"references":[{"citation":"Patel J, Meng J, Le H, Tanaka Y, Phani S, Salas M, Wu C, Sternberg D, Esker S, Anderson JP, Crowley A, Zhou SQ, Lieb C, Sun H, Doan QV, Santhanagopal A, Reckamp KL. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy. Adv Ther. 2024 Aug;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024 Jul 3.","pmid":"38958845","type":"DERIVED"},{"citation":"Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.","pmid":"37689979","type":"DERIVED"},{"citation":"Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Janne PA. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol. 2023 Jun;19(19):1319-1329. doi: 10.2217/fon-2022-1250. Epub 2023 May 22.","pmid":"37212796","type":"DERIVED"}],"start_date":{"date":"2021-02-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04619004"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04619004"}